Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Klara E. Noble-Orcutt"'
Autor:
Zohar Sachs, Raha A. Been, Krista J. DeCoursin, Hanh T. Nguyen, Nurul A. Mohd Hassan, Klara E. Noble-Orcutt, Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, Diane E. Hasz, Kelly J. Morgan, Margaret L. MacMillan, Kevin M. Shannon, David A. Largaespada, Stephen M. Wiesner
Publikováno v:
Haematologica, Vol 101, Iss 10 (2016)
Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation. Patients with neurofibromatosis type 1 harbor loss-
Externí odkaz:
https://doaj.org/article/0c115551dbd74a709612604e548eed3a
Autor:
Marie Lue Antony, Daniel Chang, Klara E. Noble-Orcutt, Anna Kay, Jeffrey L. Jensen, Hesham Mohei, Chad L. Myers, Karen Sachs, Zohar Sachs
Publikováno v:
Leukemia & Lymphoma. :1-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a826f56bc0e2dedf8bd46c029660875
https://doi.org/10.1080/10428194.2023.2207698
https://doi.org/10.1080/10428194.2023.2207698
Autor:
Morito Kurata, Marie Lue Antony, Klara E. Noble-Orcutt, Susan K. Rathe, Yoonkyu Lee, Hidehiro Furuno, Sachiko Ishibashi, Masumi Ikeda, Kouhei Yamamoto, Masanobu Kitagawa, David A. Largaespada, Zohar Sachs
Publikováno v:
Mol Cancer Res
NRAS proteins are central regulators of proliferation, survival, and self-renewal in leukemia. Previous work demonstrated that the effects of oncogenic NRAS in mediating proliferation and self-renewal are mutually exclusive within leukemia subpopulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b965fb846bdb5d3e3d0812e8ba4dac5f
https://doi.org/10.1158/1541-7786.mcr-22-0109
https://doi.org/10.1158/1541-7786.mcr-22-0109
Autor:
Zohar Sachs, David A. Largaespada, Masanobu Kitagawa, Kouhei Yamamoto, Masumi Ikeda, Sachiko Ishibashi, Hidehiro Furuno, Yoonkyu Lee, Susan K. Rathe, Klara E. Noble-Orcutt, Marie Lue Antony, Morito Kurata
NRAS proteins are central regulators of proliferation, survival, and self-renewal in leukemia. Previous work demonstrated that the effects of oncogenic NRAS in mediating proliferation and self-renewal are mutually exclusive within leukemia subpopulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79ba845757c94e1360f055e8eafe0367
https://doi.org/10.1158/1541-7786.c.6545382.v1
https://doi.org/10.1158/1541-7786.c.6545382.v1
Autor:
Zohar Sachs, David A. Largaespada, Masanobu Kitagawa, Kouhei Yamamoto, Masumi Ikeda, Sachiko Ishibashi, Hidehiro Furuno, Yoonkyu Lee, Susan K. Rathe, Klara E. Noble-Orcutt, Marie Lue Antony, Morito Kurata
Supplementary Data from Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0734844c1597b8b9c5a70c0c42faeab7
https://doi.org/10.1158/1541-7786.22527318
https://doi.org/10.1158/1541-7786.22527318
Autor:
Zohar Sachs, David A. Largaespada, Masanobu Kitagawa, Kouhei Yamamoto, Masumi Ikeda, Sachiko Ishibashi, Hidehiro Furuno, Yoonkyu Lee, Susan K. Rathe, Klara E. Noble-Orcutt, Marie Lue Antony, Morito Kurata
Supplementary Figure from Proliferation and Self-Renewal Are Differentially Sensitive to NRASG12V Oncogene Levels in an Acute Myeloid Leukemia Cell Line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397e55809f1ad452f8c802ca4b68cf89
https://doi.org/10.1158/1541-7786.22527315
https://doi.org/10.1158/1541-7786.22527315
Autor:
Zohar Sachs, David A. Largaespada, Chad L. Myers, Michael A. Linden, Matthew L. Schomaker, Matthew M. Meredith, Michael R. Verneris, Rachel J. Bergerson, Fatma K. Karadag, Conner J. Hansen, Ngoc A. Ha, Ian R. Nykaza, Alexandria L. Hillesheim, Connor M. Navis, Yoonkyu Lee, Daniel Chang, Marie Lue Antony, Rebecca S. LaRue, Klara E. Noble-Orcutt, Aaron L. Sarver, Karen Sachs
Supplementary Materials and Methods and Figures. Suppl Figs: SF1. Workflow; SF2: Cell Surface Markers; SF3: HSPC Markers; SF4: Human AML, SF5: Sorting Strategy, SF6: Post-sort; SF7: Viability and Immunophenotype; SF8: CD36 and CD69 in Human AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a68d2ddb5981e42b2ca9e713153494
https://doi.org/10.1158/0008-5472.22424277.v1
https://doi.org/10.1158/0008-5472.22424277.v1
Autor:
Zohar Sachs, David A. Largaespada, Chad L. Myers, Michael A. Linden, Matthew L. Schomaker, Matthew M. Meredith, Michael R. Verneris, Rachel J. Bergerson, Fatma K. Karadag, Conner J. Hansen, Ngoc A. Ha, Ian R. Nykaza, Alexandria L. Hillesheim, Connor M. Navis, Yoonkyu Lee, Daniel Chang, Marie Lue Antony, Rebecca S. LaRue, Klara E. Noble-Orcutt, Aaron L. Sarver, Karen Sachs
Supplementary Tables: ST1: Differentially Expressed Genes; ST2: IPA, ST3: Clinical Data, ST4: Mutational Profiles, ST5: qPCR Gene Panel, ST6: qPCR Enriched, ST7: NGS Gene panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60483820bbf9de505f52a46c5156587e
https://doi.org/10.1158/0008-5472.22424274.v1
https://doi.org/10.1158/0008-5472.22424274.v1
Autor:
Zohar Sachs, David A. Largaespada, Chad L. Myers, Michael A. Linden, Matthew L. Schomaker, Matthew M. Meredith, Michael R. Verneris, Rachel J. Bergerson, Fatma K. Karadag, Conner J. Hansen, Ngoc A. Ha, Ian R. Nykaza, Alexandria L. Hillesheim, Connor M. Navis, Yoonkyu Lee, Daniel Chang, Marie Lue Antony, Rebecca S. LaRue, Klara E. Noble-Orcutt, Aaron L. Sarver, Karen Sachs
Standard chemotherapy for acute myeloid leukemia (AML) targets proliferative cells and efficiently induces complete remission; however, many patients relapse and die of their disease. Relapse is caused by leukemia stem cells (LSC), the cells with sel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e81b3f262f9c3c84ead08aab90f0989
https://doi.org/10.1158/0008-5472.c.6511725.v1
https://doi.org/10.1158/0008-5472.c.6511725.v1
Publikováno v:
Blood Cancer Discovery. 4:A56-A56
AML with TP53 mutations (TP53Mut) is a poor-risk AML subtype that is largely insensitive to chemotherapy, targeted agents, and hematopoietic stem cell transplantation. TP53Muts are seen in approximately 10-20% of AML and confer a particularly poor pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b22a63fc80b2333407e34210091993ad
https://doi.org/10.1158/2643-3249.aml23-a56
https://doi.org/10.1158/2643-3249.aml23-a56